埼玉医科大学雑誌 第31巻 第3号別頁 (2004年7月) T35-T43頁 ◇論文(図表を含む全文)は，PDFファイルとなっています．
Serum Thymidine Kinase and Soluble Interleukin-2 Receptor Levels Predict Subclinical Recurrence of Malignant Lymphoma
Daisuke Wakao (First Department of Internal Medicine, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, Japan )
Before and after anti-neoplastic chemotherapy, serum thymidine kinase (TK) and soluble interleukin-2 receptor (sIL-2R) levels were serially determined in 28 patients with malignant lymphoma (ML). In 15 patients achieving and maintaining complete remission (CR) for more than 2 years, serum TK and sIL-2R levels were unchanged or decreased gradually. In contrast, logarithmic linear increases in TK and sIL-2R levels were observed in 13 relapsed patients. The increments of the serum markers preceded more than 10 months before the relapses. A significant positive correlation between the slope of the line for TK and that for sIL-2R was noted. The doubling time for TK estimated from the slope also showed a positive correlation with that for sIL-2R. Taken together, serum TK and sIL-2R were shown to be quite sensitive and interrelated serum markers for the recurrence of ML. Slopes of logarithmic linear increase, which are proper and specific for the individual patients, are inversely correlated with the doubling time and reflect proliferation of ML. We compared serum TK/sIL-2R and international prognostic index (IPI) for the detection of relapse of ML. IPI is widely used for individual evaluation of prognosis of ML. We conclude that serum TK and sIL-2R are better predictor of relapse than LDH and IPI.
Keywords: thymidine kinase, soluble interleukin-2 receptor, recurrence, logarithmic linear increase, proliferation of lymphoma cells